Objectives: To study the comparative mortality associated with carbapenems and alternative antibiotics for the treatment of patients with extended-spectrum b-lactamase (ESBL)-positive Enterobacteriaceae bacteraemia.
Introduction
Extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae have been increasingly implicated in healthcareassociated infections. 1 -5 Carbapenems have been considered the treatment of choice. 1 -5 However, the emergence of community-associated ESBL-positive infections 6, 7 and increasing rates of carbapenem resistance in Enterobacteriaceae as well as other bacteria 8 necessitate a more judicious use of carbapenems. Cephalosporins have been associated with higher mortality even when the MIC for Enterobacteriaceae was within the susceptible range, 9,10 fluoroquinolone use is restricted by the frequently observed coexistence of ESBLs with mechanisms that mediate fluoroquinolone resistance 11 and data on effectiveness of empirical treatment with aminoglycosides, sulphonamides, tigecycline, colistin or fosfomycin are limited. 1, 9, 12 b-Lactam/b-lactamase inhibitor combinations (BL/BLIs) have emerged as possible alternatives with the possible advantage of low association with development of infections caused by ESBL-producing bacteria. 13 A post-hoc analysis of six prospective studies suggested that there was no difference in mortality between carbapenems and BL/BLIs for the treatment of ESBL-positive Escherichia coli bacteraemia. 14 We systematically reviewed the published evidence to study the comparative mortality associated with carbapenems and alternative antibiotics for the treatment of patients with ESBL-positive Enterobacteriaceae bacteraemia.
Methods
Literature search and study selection Scopus and PubMed databases were searched until January 2012. The following search pattern was applied: (ESBL OR extended-spectrum b-lactamases) and (bacteraemia OR bloodstream infections). References of retrieved articles were hand searched. Articles published in languages other than English, Spanish, German, French, Italian or Greek were not eligible for inclusion.
Any published article reporting data on mortality of patients with bacteraemia due to ESBL-positive Enterobacteriaceae was considered eligible. Studies were included if they reported the mortality of patients receiving empirical or definitive treatment with any carbapenem in comparison with any other antibiotic, preferably administered as monotherapy. Patients of all ages with community-, hospital-and healthcare-associated bacteraemia were eligible for inclusion. Studies in which all patients received only carbapenems were excluded. Studies that included infections other than bacteraemia (primary, secondary or catheter related) were also excluded, as were case reports and abstracts from conferences.
Data extraction
Literature search, study selection and data extraction were performed independently by two investigators (G. S. T. and K. Z. V.). Any disagreement was resolved by consensus in meetings with all investigators. The extracted data included the characteristics of each study, its patient population, the studied pathogens, the testing method used for ESBL identification and its clinical outcomes. The corresponding authors were contacted via e-mail to provide outcome data according to the empirically or definitively prescribed antibiotics when such data were not available in the full article.
Definitions and outcomes
The outcome of this meta-analysis was the comparative all-cause mortality of patients receiving carbapenems or alternative antibiotics for bacteraemia due to ESBL-positive Enterobacteriaceae (and in the subsets of patients with bacteraemia due to E. coli and Klebsiella pneumoniae, if such data were available) as empirical or definitive treatment. The point at which mortality was recorded was the timepoint set in each study. Carbapenems were compared with BL/BLIs, non-BL/BLIs (all other antibiotics), fluoroquinolones, cephalosporins and all alternative antibiotics (BL/BLIs and non-BL/BLIs) in the primary analysis. In a secondary analysis, BL/BLIs were compared with non-BL/BLIs.
The definitions of nosocomial, healthcare-associated or communityonset bacteraemia were based on the definitions provided by each study. In general, bacteraemia was defined by the presence of at least one blood culture growing Enterobacteriaceae in addition to symptoms and signs compatible with bacteraemia and systemic inflammatory response syndrome (fever or hypothermia, systolic blood pressure ,90 mmHg, tachycardia .90 beats/min and white blood cell count .11 000 cells/mL or ,4000 cells/mL).
Empirical treatment was defined as prescription of antibiotics before culture results were available; empirical treatment was considered appropriate when the isolated pathogen was susceptible in vitro to the empirically administered antibiotic according to the CLSI breakpoints at the time of the study. Patients receiving empirical therapy with one class of antibiotics were included in the empirical treatment analysis regardless of the definitively administered regimen, unless they were excluded from the final analysis of the original study. Modification of treatment was defined as change to an effective antibiotic after the culture result was available according to the pathogen's susceptibility pattern. Definitive therapy was defined as appropriate empirical treatment plus correctly modified therapy.
Statistical analysis
Pooled risk ratios (RRs) and 95% CIs were calculated regarding all outcomes. Statistical heterogeneity between studies was assessed using a x 2 -test (P, 0.10 was defined to indicate significant heterogeneity) and I 2 to denote the degree of heterogeneity (0%-40% no heterogeneity, 30%-60% moderate heterogeneity, 50%-90% substantial heterogeneity, 75%-100% considerable heterogeneity). The Mantel-Haenszel (M-H) fixed-effect model (FEM) was used when there was no significant statistical heterogeneity between the studies; otherwise, the DerSimonian-Laird random-effects model (REM) was used. Publication bias was assessed by the funnel plot method. The meta-analysis was performed with Review Manager for Windows, version 5.1. The Newcastle-Ottawa scale for assessment of risk of bias in nonrandomized studies was used.
Results Figure 1 shows the process for selection of the eligible studies. Forty-one articles did not report the required data and their corresponding authors were contacted. Three of them provided the requested data (one provided data for two articles); 15 -18 data from one article could not be used because patients with and without bacteraemia were included. 15 Thus, of the retrieved articles, 21 were included in the meta-analysis. 14,16 -35 One of the included studies was a post-hoc analysis of six prospective studies 14 in which the authors used only data regarding the comparative mortality of patients treated with carbapenems and BL/BLIs. However, two of these six studies also provided data regarding mortality of patients treated with non-BL/BLIs. These data were also used. 36, 37 Table 1 shows the characteristics of the included studies. The focus of the meta-analysis was similar to the scope of seven of the included studies. 14, 19, 23, 30, 31, 33, 35 Sixteen were retrospective 14,16 -18,20,23 -26,28 -32,34,35 and five were prospective. 19, 21, 22, 27, 33 Sixteen studies were conducted after the year 2000, 14,16 -23,26 -28,30 -32,34 two before 2000 24, 33 and three enrolled patients from both periods. 25, 29, 35 Most were single-centre studies, and were performed in Asia, 16,19,21,24,28 -32 Europe 14,23,25 -27,35 or America; 17, 18, 22, 34 one study was international 33 and one was conducted in South Africa. 20 Three studies were funded by pharmaceutical companies 18, 22, 34 and one by a pharmaceutical company and a physician association. 33 In-hospital mortality was reported in four studies, 19, 22, 24, 25 28 or 30 day mortality in 10 studies, 14,16 -18,21,27 -31,34 21 day mortality in two studies 23, 35 and 14 day mortality in four studies. 20,31 -33 One study did not specify when mortality was assessed. 26 Most of the enrolled patients had significant comorbidity that included solid organ or haematological malignancies, neutropenia, diabetes mellitus, chronic kidney or cardiovascular disease, prior hospitalization or antibiotic use. Communityassociated, healthcare-associated and nosocomial episodes of Systematic review bacteraemia were studied together. E. coli and K. pneumoniae were the most frequently studied pathogens.
Predictors of mortality identified in the individual studies included severity of bacteraemia [as measured by Pitt bacteraemia score, septic shock, APACHE (acute physiological assessment and chronic health evaluation ) II score, pneumonia or peritonitis, and intensive care unit (ICU) admission], 14,16,20,23,26 -33,35 and inappropriate empirical treatment. 24, 35 Appropriate empirical treatment ranged from 22% to 100%; 5 out of 13 studies that provided data reported that the proportion of patients receiving appropriate empirical treatment was lower than 50%; 16, 18, 19, 26, 27 7 reported that 50% -70% of patients received appropriate empirical treatment. 17,21 -23,25,32,35 In addition, a delay in the prescription of an appropriate regimen between 1 and 6 days was reported. Appropriate treatment was associated with lower mortality than inappropriate treatment (RR 0.64, 95% CI 0.46-0.88). Table 2 shows the available data regarding mortality of 1584 patients with ESBL-positive bacteraemia included in the metaanalysis according to the definitively or empirically administered antibiotic. Table 3 summarizes the results of the meta-analysis. Publication bias was detected. Overall, carbapenems were more frequently used as definitive ( 35 patients per study reporting data) than as empirical ( 24 patients per study reporting data) antibiotic therapy. BL/BLIs were more frequently used as empirical (21 patients per study) than as definitive (11 patients per study) therapy. Besides BL/BLIs, cephalosporins, fluoroquinolones and aminoglycosides were used with decreasing frequency for the treatment of patients with ESBL-positive bacteraemia.
Data regarding mortality for patients treated definitively and empirically with carbapenems versus BL/BLIs were available from 11 and 13 studies, respectively. No difference in mortality was observed between carbapenems and BL/BLIs for both definitive (RR 0.52, 95% CI 0.23 -1.13; Figure 2 ) and empirical (RR 0.91, 95% CI 0.66 -1.25; Figure 3 ) treatment. Data regarding mortality of patients treated definitively and empirically with carbapenems and non-BL/BLI antibiotics were available from 13 and 11 studies, respectively. Mortality was lower with carbapenem than with non-BL/BLI antibiotic treatment for both definitive (RR 0.65, 95% CI 0.47-0.91; Figure 4 ) and empirical (RR 0.50, 95% CI 0.33 -0.77; Figure 5 ) treatment. Carbapenems were not associated with lower mortality when they were compared with all studied antibiotics for empirical (RR 0.76, 95% CI 0.56 -1.02) or definitive (RR 0.80, 95% CI 0.51-1.26) treatment. Carbapenems were associated with lower mortality than cephalosporins for both definitive (RR 0.34, 95% CI 0.22 -0.52) and empirical (RR 0.51, 95% CI 0.32 -0.82) treatment, and with lower mortality than fluoroquinolones for empirical (RR • Data for mortality were not available (n = 8) • One antibiotic was studied (n = 6) • Data for bacteraemia were not available (n = 9) • Article was part of other studies (n = 8)
Full-text articles-communication with corresponding authors (n = 59)
Full-text articles excluded (n = 38)
• Authors did not respond (n = 27) • Authors responded that data were not available (n = 8) • Authors offered to provide data, but did not send the data (n = 2)
• The author provided the data, but the data were not included because other infections were also studied (n = 1)
Studies included (n = 21)
Studies excluded as irrelevant to the focus of the metaanalysis K. pneumoniae NAV 6 NAV NAV CHF, chronic heart failure; CO, community onset; COPD, chronic obstructive pulmonary disease; CRD/F, chronic renal disease/failure; CVD, cardiovascular disease; DM, diabetes mellitus; HCA, healthcare associated; HM, haematological malignancies; IMC, immunocompromised; MC, multicentre; NAV, not available; OLT, orthotopic liver transplantation; SC single centre, UD, undefined location of bacteraemia acquisition. a The data were not included in the methodology, but were suggested by the results. b Data from this study are a summary of six prospective studies for carbapenems and BL/BLIs; data for the remaining antibiotics were available from two of these studies (references 36 and 37). Data regarding the onset of bacteraemia (community, healthcare or nosocomial), its primary source (primary or secondary), ESBL identification method, Newcastle -Ottawa scale, study design, time of mortality assessment and specific bacterial species were limited and prohibited meaningful comparisons. Separate data for the outcome of patients who received a different empirical and definitive regimen were also not available. In addition, the data from the studies that evaluated mortality of patients infected specifically by E. coli or K. pneumoniae were too limited to allow for meaningful comparisons as the authors either studied a small number of patients or did not provide data for all antibiotic comparisons. Finally, the outcomes were not different between prospective and retrospective studies.
Discussion
Carbapenems were associated with lower mortality than non-BL/ BLIs for both definitively and empirically treated patients with ESBLpositive bacteraemia. There was no difference in mortality when carbapenems were compared with BL/BLIs alone or with all alternative antibiotics. Carbapenems were used as definitive treatment more frequently than as empirical treatment. Finally, BL/BLIs were not associated with lower mortality than non-BL/BLIs. Although no statistical difference in mortality was shown between carbapenems and BL/BLIs, several issues need to be addressed. First, several of the patients who received empirical treatment with BL/BLIs finally received definitive therapy with carbapenems. As a result, we cannot conclude whether the observed mortality among patients on BL/BLIs should be attributed solely to these antibiotics. This clinical heterogeneity might explain the substantial statistical heterogeneity observed in the analysis of definitive treatment. Second, BL/BLIs can be inactivated by the presence of b-lactamases that do not belong to the ESBL group. There is also evidence that the MICs of piperacillin/tazobactam depend on the bacterial load; when the inoculum rises, so does the MIC. In addition, reduced activity of b-lactamase inhibitors has been documented due to porin loss in ESBL-positive strains. 5 The resistance rate among ESBL-producing Enterobacteriaceae was higher to BL/BLIs than to carbapenems. The included studies reported that susceptibility of ESBL-producing Enterobacteriaceae to amoxicillin/clavulanate ranged from 4% to 100%, while susceptibility to piperacillin/tazobactam varied from 22% to 100%. Proteus mirabilis was the microorganism most susceptible to both antibiotics ( 100% in all of the included studies). On the other hand, the susceptibility of E. coli varied between 4% and 67% for amoxicillin/clavulanate and between 22% and Systematic review 95% for piperacillin/tazobactam and the susceptibility of K. pneumoniae ranged from 54% to 64% for piperacillin/tazobactam. The susceptibility of the studied Enterobacteriaceae to carbapenems ranged from 95% to 100%. 16,23,26,32,35 -37 In fact, only two studies reported that the susceptibility of K. pneumoniae strains to carbapenems was 95%, while in all others all isolates were susceptible to carbapenems. Other studies not included in the meta-analysis showed similar susceptibility trends, 38 -41 suggesting that appropriate empirical treatment could be attained more often with prescription of carbapenems.
The choice of the empirical regimen depends on several parameters, including the history of the patient, the severity of bacteraemia, its primary site and the local patterns of susceptibility. It has been suggested that a non-urinary source of ESBL-positive bacteraemia is associated with higher mortality, 14, 26 while an unidentified source of bacteraemia is associated with worse outcomes. 35 In addition, the outcome of infections depends on the implementation of additional therapeutic measures, including surgical procedures. Finally, physicians may select a broaderspectrum antibiotic or a combination of antibiotics for more severe infections. Since none of the studies included in the meta-analysis was a randomized controlled trial and data were not available for sensitivity analyses according to the aforementioned factors, their contribution to patient outcomes could not be estimated.
When interpreting the results of this meta-analysis we must also consider its limitations. First, most of the included studies were not designed to study the alternative options to carbapenems for ESBL-positive Enterobacteriaceae bacteraemia. Thus, data were not available to adjust for confounding factors. Second, several antibiotics of the same class had been used for both carbapenems and their comparators. In addition, although the majority of studies reported on appropriate empirical antibiotic treatment, they did not report outcomes on adequate treatment (plus correct dosing, sufficient duration of administration and so on). 42 Third, although only studies on patients with ESBL-positive bacteraemia were included in the meta-analysis, their populations were heterogeneous since the source of bacteraemia varied significantly between studies. In addition, although E. coli and K. pneumoniae bacteraemias were predominantly studied, Enterobacter spp. and P. mirabilis bacteraemias were also included. It has been suggested that bacteraemia due to K. pneumoniae is associated with higher mortality than E. coli bacteraemia. 19 Unfortunately, the available data precluded a meaningful analysis according to specific species.
Fourth, patients with community-associated, healthcareassociated and nosocomial bacteraemia were included. It is possible that variables that might influence mortality can be found less commonly in patients in the first group.
Fifth, several of the included studies were performed years ago; since then, breakpoints of several antibiotics for Enterobacteriaceae have changed, and it is possible that strains that were considered susceptible to non-carbapenem antibiotics at the time of the study were in fact resistant. 43, 44 Although carbapenem breakpoints have also decreased, 43 the available data suggest that carbapenems have the lowest MIC values among Enterobacteriaceae. 45 -50 Sixth, in some studies it was impossible to discriminate between patients treated with monotherapy or a combination of antibiotics. In addition, the available data precluded such an analysis because either the proportion of patients receiving combination therapy was negligible or it was not consistently reported as definitive or empirical treatment. 20, 21, 24, 25, 27, 28 However, there is no clinical evidence thus far that the combination of antibiotics is associated with lower mortality in patients with ESBL-positive bacteraemia. 24, 28, 33, 46 Publication bias was detected using the funnel plot. It is suggested that the funnel plot should not be used alone; however, for dichotomous outcomes with intervention effects measured as RRs 'the potential problems in funnel plots have been less extensively studied for these effect measures than for ORs, and firm guidance is not yet available as to the model that can be used to explore further a possible asymmetry'. 51 In conclusion, carbapenems may be considered the treatment of choice for the empirical treatment of patients with ESBLproducing Enterobacteriaceae bacteraemia. BL/BLIs may provide an appropriate, alternative treatment option, and-at least in Against non-BL/BLIs Against carbapenems Systematic review some settings-can be used as carbapenem-sparing antibiotics. BL/BLIs can be probably considered effective in definitive therapy for community-associated infections, where the rate of resistance should be considered lower, and in hospital settings with a low level of resistant bacteria. On the other hand, carbapenems should be considered in settings with a high frequency of bacterial resistance or during outbreaks, mainly because of their better in vitro activity compared with BL/BLIs. The role of BL/BLIs as definitive treatment for ESBL-positive bacteraemia should be further studied.
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